Patent Summary: "Difluorohexahydrocyclopentaoxazinyls and difluorohexa-benzooxazinyls as inhibitors of bace1". The present invention provides difluoro-cyclopentaoxazinyls and difluoro-oxazinyls of formula I with bace1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and / or prophylactic treatment, for example, of Alzheimer's disease. i hardy et al., the amyloid hypothesis of alzheimer's disease: progress and problems on the road to therapeutics, science. July 19, 2002； 297 (5580): 353-6, ii selkoe, cell biology of the amyloid beta-protein precursor and the mechanism of alzheimer's disease, annu rev cell biol. 1994； 10: 373-403 iii vassar et al., Beta-secretase cleavage of alzheimer's amyloid precursor protein by the aspartic protease bace transmembrane, science. October 22, 1999； 286 (5440): 735 iv luo et al., Mice deficient in bace1, the alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation, nat neurosci. March 2001； 4 (3): 231-2 v roberds et al., Bace knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for alzheimer's disease therapeutics, a mole genet. June 1, 2001； 10 (12): 1317-24 vi mcconlogue et al., Partial reduction of bace1 has dramatic effects on alzheimer's plaque and synaptic pathology in app transgenic mice. j biol chem. September 7, 2007； 282 (36): 26326 vii 2011071135 viii biochem. pharmacol. (1973) 22: 3099 IX Compendium of Chemical Terminology, 2nd Edition, a. d. Mcnaught & a. Wilsonkins (eds). blackwell scientific publications, oxford (1997) x brockhaus et al., neuroreport 9, 1481-1486； 1998 xi r.l.walsky and r.s.obach, drug metabolism and disposition 32: 647-660, 2004. and s.fowler and h.zhang, the aaps journal, vol.10, no. 2, 410-424, 2008 xii guo l, guthrie h, automated electrophysiology in the preclin
